Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder
Abstract JNJ-54175446 is a selective purine P2X7 receptor (P2X7R) antagonist that attenuates microglial IL-1β/IL-18 release. In healthy volunteers, JNJ-54175446 suppressed peripheral interleukin (IL)-1β release, and attenuated dexamphetamine-induced improvements of mood and (visuo)motor performance...
Main Authors: | Kasper Recourt, Peter de Boer, Peter van der Ark, Heike Benes, Joop M. A. van Gerven, Marc Ceusters, Luc van Nueten, Wayne C. Drevets, Anindya Bhatacharya, Michael Browning, Gabriel E. Jacobs |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2023-07-01
|
Series: | Translational Psychiatry |
Online Access: | https://doi.org/10.1038/s41398-023-02557-5 |
Similar Items
-
Anti-seizure effects of JNJ-54175446 in the intra-amygdala kainic acid model of drug-resistant temporal lobe epilepsy in mice
by: Omar Mamad, et al.
Published: (2024-01-01) -
Translational Model‐Informed Dose Selection for a Human Positron Emission Tomography Imaging Study of JNJ‐54175446, a P2X7 Receptor Antagonist
by: Yan Xu, et al.
Published: (2020-03-01) -
Ketamine effects on resting state functional brain connectivity in major depressive disorder patients: a hypothesis-driven analysis based on a network model of depression
by: Kasper Recourt, et al.
Published: (2025-02-01) -
Dataset of eyeblink conditioning in mice treated with the selective mGluR1 antagonist JNJ16259685
by: Shoichi Tohyama, et al.
Published: (2023-04-01) -
Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study
by: Maarten Timmers, et al.
Published: (2018-08-01)